These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29055158)

  • 21. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial.
    Abels C; Soeberdt M; Kilic A; Reich H; Knie U; Jourdan C; Schramm K; Heimstaedt-Muskett S; Masur C; Szeimies RM
    Br J Dermatol; 2021 Aug; 185(2):315-322. PubMed ID: 33445205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study.
    Glogau RG
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S76-80. PubMed ID: 17241418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
    Lowe NJ; Glaser DA; Eadie N; Daggett S; Kowalski JW; Lai PY;
    J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis.
    Talarico-Filho S; Mendonça DO Nascimento M; Sperandeo DE Macedo F; DE Sanctis Pecora C
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S44-50. PubMed ID: 17241414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial.
    Cahn A; Mehta R; Preece A; Blowers J; Donald A
    Clin Drug Investig; 2013 Sep; 33(9):653-64. PubMed ID: 23881566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD.
    Feldman G; Maltais F; Khindri S; Vahdati-Bolouri M; Church A; Fahy WA; Trivedi R
    Int J Chron Obstruct Pulmon Dis; 2016; 11():719-30. PubMed ID: 27103795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.
    Hebert AA; Glaser DA; Green L; Hull C; Cather J; Drew J; Gopalan R; Pariser DM
    Pediatr Dermatol; 2020 May; 37(3):490-497. PubMed ID: 32147881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial.
    Kirsch B; Smith S; Cohen J; DuBois J; Green L; Baumann L; Bhatia N; Pariser D; Liu PY; Chadha D; Walker P
    J Am Acad Dermatol; 2020 Jun; 82(6):1321-1327. PubMed ID: 32068049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topical atropine sulfate for the treatment of axillary hyperhidrosis.
    Grimalt R; Domínguez Tordera P; Callejas MA
    J Cosmet Dermatol; 2006 Dec; 5(4):294-6. PubMed ID: 17716247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
    Lee L; Kerwin E; Collison K; Nelsen L; Wu W; Yang S; Pascoe S
    Respir Med; 2017 Oct; 131():148-157. PubMed ID: 28947022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
    Sousa AR; Riley JH; Church A; Zhu CQ; Punekar YS; Fahy WA
    NPJ Prim Care Respir Med; 2016 Jun; 26():16031. PubMed ID: 27334739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
    Maleki-Yazdi MR; Kaelin T; Richard N; Zvarich M; Church A
    Respir Med; 2014 Dec; 108(12):1752-60. PubMed ID: 25458157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study.
    Lee LA; Yang S; Kerwin E; Trivedi R; Edwards LD; Pascoe S
    Respir Med; 2015 Jan; 109(1):54-62. PubMed ID: 25452139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
    Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients.
    Kim WO; Kil HK; Yoon KB; Yoo JH
    Acta Derm Venereol; 2010 May; 90(3):291-3. PubMed ID: 20526549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label tolerability and efficacy study of an aluminum sesquichlorohydrate topical foam in axillary and palmar primary hyperhidrosis.
    Innocenzi D; Ruggero A; Francesconi L; Lacarrubba F; Nardone B; Micali G
    Dermatol Ther; 2008 Jul; 21 Suppl 1():S27-30. PubMed ID: 18727813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.
    Hu C; Jia J; Dong K; Luo L; Wu K; Mehta R; Peng J; Ren Y; Gross A; Yu H
    PLoS One; 2015; 10(3):e0121264. PubMed ID: 25816315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: A randomized, double-blind, vehicle-controlled study.
    Yokozeki H; Fujimoto T; Wanatabe S; Ogawa S; Fujii C
    J Dermatol; 2022 Jan; 49(1):86-94. PubMed ID: 34636057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of oxybutynin for treating axillary hyperhidrosis.
    Wolosker N; de Campos JR; Kauffman P; Neves S; Munia MA; BiscegliJatene F; Puech-Leão P
    Ann Vasc Surg; 2011 Nov; 25(8):1057-62. PubMed ID: 22023940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
    Wolosker N; de Campos JR; Kauffman P; Puech-Leão P
    J Vasc Surg; 2012 Jun; 55(6):1696-700. PubMed ID: 22341836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.